ROMERIO ALESSIO
Pubblicazioni
Franco, A., Aladailleh, Z., Romerio, A., Italia, A., Lami, F., Shaik, M., et al. (2025). Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists. RSC MEDICINAL CHEMISTRY, 16(5), 2261-2269 [10.1039/D4MD00950A]. Dettaglio
Sainz-Mejias, M., Ma, C., Hou, Y., Jurado-Martin, I., Romerio, A., Franco, A., et al. (2025). Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against Pseudomonas aeruginosa Challenge. ACS INFECTIOUS DISEASES, 11(4), 894-904 [10.1021/acsinfecdis.4c00932]. Dettaglio
Shirey, K., Romerio, A., Shaik, M., Leake, D., Palmer, C., Skupinska, N., et al. (2025). Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection. INNATE IMMUNITY, 31 [10.1177/17534259241313201]. Dettaglio
Italia, A., Franco, A., Shaik, M., Romerio, A., Lami, F., Lovisa, S., et al. (2024). Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases. Intervento presentato a: XXVIII Congresso Nazionale della Società Chimica Italiana - 26th - 30th of August 2024, Allianz MiCo Congress Center in Milan. Dettaglio
Ami, D., Franco, A., Artusa, V., Romerio, A., Shaik, M., Italia, A., et al. (2024). Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists. TALANTA, 275(1 August 2024) [10.1016/j.talanta.2024.126104]. Dettaglio